Scinai Immunotherapeutics Ltd - Asset Resilience Ratio
Scinai Immunotherapeutics Ltd (SCNI) has an Asset Resilience Ratio of 0.93% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Scinai Immunotherapeutics Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2016)
This chart shows how Scinai Immunotherapeutics Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Scinai Immunotherapeutics Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Scinai Immunotherapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SCNI market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $138.01K | 0.93% |
| Total Liquid Assets | $138.01K | 0.93% |
Asset Resilience Insights
- Limited Liquidity: Scinai Immunotherapeutics Ltd maintains only 0.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Scinai Immunotherapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Scinai Immunotherapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Scinai Immunotherapeutics Ltd (2008–2016)
The table below shows the annual Asset Resilience Ratio data for Scinai Immunotherapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 31.98% | $2.50 Million | $7.82 Million | +27.10pp |
| 2015-12-31 | 4.88% | $517.39K | $10.60 Million | -6.04pp |
| 2014-12-31 | 10.92% | $517.41K | $4.74 Million | +3.12pp |
| 2013-12-31 | 7.80% | $580.52K | $7.45 Million | -16.23pp |
| 2012-12-31 | 24.03% | $1.50 Million | $6.22 Million | -35.10pp |
| 2011-12-31 | 59.13% | $4.24 Million | $7.16 Million | -16.19pp |
| 2010-12-31 | 75.32% | $6.54 Million | $8.68 Million | -11.25pp |
| 2009-12-31 | 86.57% | $7.75 Million | $8.95 Million | -0.34pp |
| 2008-12-31 | 86.92% | $2.78 Million | $3.20 Million | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more